Comment from Otsuka Pharmaceutical Development & Commercialization, Inc.

Summary: Otsuka Pharmaceutical Development & Commercialization, Inc. supports the FDA's effort to provide a validation framework for new approach methodologies (NAMs) in drug development. The company provides specific suggestions to clarify the requirements for validation, the intent of replacing in-vivo studies, and the need for cross-office alignment and case study examples.